Previous 10 | Next 10 |
Nautilus Biotechnology press release (NASDAQ:NAUT): Q4 GAAP EPS of -$0.13 in-line.Cash, cash equivalents, and investments were $362.1 million as of December 31, 2021. For further details see: Nautilus Biotechnology GAAP EPS of -$0.13 in-line
SEATTLE, Feb. 24, 2022 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single molecule proteome analysis platform, today reported financial results for the fourth quarter and fiscal year ended December 31, 2021. ...
Nautilus Biotechnology (NASDAQ:NAUT) is scheduled to announce Q4 earnings results on Thursday, February 24th, before market open. The consensus EPS Estimate is -$0.14 For further details see: Nautilus Biotechnology Q4 2021 Earnings Preview
ABEV,ACIW,ACRS,AEP,AGIO,AHCO,ALIM,AMT,ATHM,OTCQX:AXAHY,AZUL,BABA,BLI,BUD,CARS,CBRE,CCO,CCOI,OTCPK:CDUAF,CGEN,CLDT,CMPS,CWT,CYD,DAO,DBRG,OTCPK:DDAIF,DEN,DISCA,DISH,DOCN,OTCQX:DTEGY,EDIT,ELAN,EME,EXPI,FOLD,GCI,GLNG,GNK,GNL,GTLS,HMHC,HYLN,IBP,IMUX,IONS,IRM,ISEE,KDP,KRP,OTCPK:LBLCF,LNG,LNTH,LXP,L...
SEATTLE, Feb. 16, 2022 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule protein analysis platform for quantifying the proteome, today announced the company will be participating virtually in the upcomin...
SEATTLE, Jan. 27, 2022 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule protein analysis platform for quantifying the proteome, today announced it will report financial results for the fourth quarter an...
Nautilus Biotechnology (NAUT +9.1%) director Perceptive Advisors purchased 200,000 shares at ~$5.36 on December 8, transaction value $1.1M. This brings the total holding to 9.1M shares. Form 4 The stock jumped on December as Sujal M Patel, CEO, President bought 2.5M shares. The stock has a ma...
Penny stocks have become some of the hottest things to buy during this latest leg of the market’s bull run. Despite the pullback in the S&P 500 this week, the slight dip pales in comparison to the year-to-date move so far. This year, for example, the SPY ETF started January a...
Following a decline of ~8.3% on Wednesday, the shares of Nautilus Biotechnology (NAUT +7.4%) have rebound after the CEO of the life sciences company, Sujal Patel, disclosed the purchase of 250K company shares. According to an SEC filing on Thursday, Patel has executed the transaction early th...
Nautilus Biotechnology, Inc. (NAUT) Q3 2021 Earnings Conference Call November 2, 2021 08:30 ET Company Participants Sujal Patel - Co-Founder & Chief Executive Officer Parag Mallick - Co-Founder & Chief Scientific Officer Anna Mowry - Chief Financial Officer Conference Call Participant...
News, Short Squeeze, Breakout and More Instantly...
Nautilus Biotechnology Inc. Company Name:
NAUT Stock Symbol:
NASDAQ Market:
Nautilus Biotechnology Inc. Website:
SEATTLE, July 30, 2024 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule proteome analysis platform, today reported financial results for the second quarter ended June 30, 2024. “In Q2, we saw con...
SEATTLE, July 09, 2024 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single molecule protein analysis platform, today announced it will report financial results for the second quarter 2024 before market open on Tuesday, July 3...
SEATTLE, May 23, 2024 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule protein analysis platform, today announced the company will be participating in the Goldman Sachs 45th Annual Healthcare Conference. Nauti...